Regen BioPharma, Inc. (RGBP)

Regen BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Net Income	-1.73	-1.27	-0.67	1.16	2.44	-6.77
Other Amortization	0.05	0.05	-0.03	0	0.07	0.05
Loss (Gain) From Sale of Investments	-	-	-	-	-0.03	1.16
Stock-Based Compensation	0.52	0.13	0.2	0.25	0.05	0
Other Operating Activities	0.64	0.68	0	0.35	0	-1.87
Change in Accounts Receivable	-0.11	-0.11	-0.09	0.25	-0.04	-0.11
Change in Accounts Payable	0	0	-0	0	-0.06	-0.02
Change in Unearned Revenue	-0.13	-0.13	-0.14	-0.11	-0.13	1.84
Change in Other Net Operating Assets	0.23	0.27	-0.02	-2.07	-2.91	4.59
Operating Cash Flow	-0.52	-0.38	-0.75	-0.17	-0.61	-1.13
Investment in Securities	-	-	-	-	0.03	0.5
Investing Cash Flow	-	-	-	-	0.03	0.5
Short-Term Debt Issued	-	0.15	0.08	0.24	0	1.36
Long-Term Debt Issued	-	0.19	-	-	-	-
Total Debt Issued	0.28	0.34	0.08	0.24	0	1.36
Long-Term Debt Repaid	-	-	-0.01	-	-0.09	-
Total Debt Repaid	-0.06	-	-0.01	-	-0.09	-
Net Debt Issued (Repaid)	0.22	0.34	0.07	0.24	-0.09	1.36
Issuance of Common Stock	0.25	0.06	0.56	-	-	-
Other Financing Activities	0.05	0.05	-	-	-	-
Financing Cash Flow	0.52	0.45	0.63	0.24	-0.09	1.36
Miscellaneous Cash Flow Adjustments	0	-	-	-	-0	-
Net Cash Flow	0	0.07	-0.12	0.07	-0.68	0.73
Cash Interest Paid	-	-	-	-	0.03	-
Levered Free Cash Flow	0.18	0.55	-0.41	-2.56	-4.04	5.79
Unlevered Free Cash Flow	0.26	0.63	-0.31	-2.52	-3.98	5.97
Change in Working Capital	0	0.04	-0.25	-1.93	-3.14	6.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.